Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs Sells 8,360 Shares

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,360 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $121,888.80. Following the completion of the sale, the chief executive officer now directly owns 826,985 shares in the company, valued at $12,057,441.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Roger Jeffs also recently made the following trade(s):

• On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The shares were sold at an average price of $15.82, for a total transaction of $452,183.06.

Liquidia Stock Performance

Shares of Liquidia stock opened at $13.81 on Friday. Liquidia Co. has a 52-week low of $5.71 and a 52-week high of $16.99. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -11.51 and a beta of 0.16. The company’s 50 day moving average price is $14.75 and its 200-day moving average price is $10.95.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. The firm had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. As a group, equities research analysts forecast that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of recent research reports. LADENBURG THALM/SH SH increased their price target on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. HC Wainwright increased their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Liquidia in a research report on Wednesday, April 10th. Wedbush reiterated an “underperform” rating and set a $3.00 price target on shares of Liquidia in a research report on Thursday, December 21st. Finally, Bank of America increased their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Citigroup Inc. bought a new stake in Liquidia in the first quarter valued at $592,000. BlackRock Inc. boosted its holdings in Liquidia by 0.4% in the first quarter. BlackRock Inc. now owns 846,385 shares of the company’s stock valued at $6,077,000 after acquiring an additional 3,042 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Liquidia by 56.8% in the first quarter. Dimensional Fund Advisors LP now owns 74,307 shares of the company’s stock valued at $534,000 after acquiring an additional 26,908 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Liquidia in the first quarter valued at $86,000. Finally, Vanguard Group Inc. boosted its holdings in Liquidia by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,659,082 shares of the company’s stock valued at $11,912,000 after acquiring an additional 47,161 shares in the last quarter. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).